- Poster presentations feature preclinical in vitro and in vivo data of potentially first-in-class oral small molecule GIPR agonist ASC48 and next-generation once-monthly to once-quarterly GLP-1R/GIPR/GCGR triple peptide agonist ASC37 HONG KONG, Nov. 2, 2026 /PRNewswire/ -- Ascletis...
Hence then, the article about ascletis to present study results of oral small molecule gipr agonist asc48 and glp 1r gipr gcgr triple peptide agonist asc37 at obesityweek 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026 )
Also on site :
- 3 Meteor Showers Will Light Up the Sky in November— and One Is Known for Producing Brilliant Fireballs
- 2026 was meant to be the Philippines’ year—yet the country remains stuck in an ‘recurring cycle of underachievement’
- ‘Teen Mom’ Star Tyler Baltierra Praises Wife Catelynn After Her 30-Lb. Weight Loss: ‘I’m So Beyond Proud’